Live Query Engine — v4.2.12026-05-30 07:41:50 UTC
pharma-cli — query
CONNECTED
❯
The Pipeline Intelligence Command Center
Real-time approval probability scores, patent cliff exposure, and FDA catalyst density — rendered before pre-market opens.
Scroll to explore
PDUFA DATE TRACKINGPATENT CLIFF ANALYTICSAPPROVAL PROBABILITY SCORINGCOMPETITIVE LANDSCAPEFDA CATALYST CALENDARPIPELINE INTELLIGENCENCE MONITORINGPHASE TRANSITION PROBABILITIESBD TARGET SCREENINGPDUFA DATE TRACKINGPATENT CLIFF ANALYTICSAPPROVAL PROBABILITY SCORINGCOMPETITIVE LANDSCAPEFDA CATALYST CALENDARPIPELINE INTELLIGENCENCE MONITORINGPHASE TRANSITION PROBABILITIESBD TARGET SCREENING
0
Active PDUFA Dates0
Phase Readouts Tracked0+
Historical FDA Decisions0.00
Model AUC Score0.00%
Avg LoA Rate (Phase I→Approval)$0B+
USD Revenue at Patent Risk 2025–30Interactive Pipeline Explorer
Filter. Query. Decide.
Toggle filters to reshuffle 12 tracked candidates across 7 therapeutic areas.
Sort:
Therapeutic Area
Phase
Designation
12 candidates
IDCompoundAreaPhPDUFAPoA ScoreT-MinusDesig.
BLA-2025-0892Ifinatamab deruxtecanOncologyII2026-02-14PastBREAKTHROUGH
55%PoA
NDA-2026-0189CagriSemaObesityIII2026-03-28PastPRIORITY
74%PoA
BLA-2026-0098DatopotamabOncologyIII2026-04-22PastSTANDARD
71%PoA
BLA-2026-0211TarlatamabOncologyIII2026-05-18PastBREAKTHROUGH
77%PoA
NDA-2026-0412ZilganersenNeurologyIII2026-06-1516dORPHAN
68%PoA
BLA-2026-0301ZanidatamabOncologyII2026-06-304wBREAKTHROUGH
67%PoA
NDA-2026-0389LerodalcibepCardiovascularIII2026-07-096wSTANDARD
65%PoA
NDA-2026-0557ImetelstatHematologyIII2026-08-303moORPHAN
59%PoA
BLA-2026-0134MirdametinibOncologyIII2026-09-033moORPHAN
63%PoA
NDA-2026-0476DeuruxolitinibImmunologyIII2026-10-215moSTANDARD
58%PoA
NDA-2026-0341OrforglipronMetabolicIII2026-11-146moSTANDARD
82%PoA
NDA-2026-0623SetmelanotideMetabolicII2026-12-056moORPHAN
61%PoA
Showing 12 of 12 tracked candidates · Full access requires institutional emailUnlock full pipeline →
Patent Cliff Exposure Matrix
$230B+ Revenue at Risk
Patent expiry timeline across major franchises, 2024–2032. Revenue figures in USD billions.
Critical (expiry yr)
High risk
Watch
Expired
pharma.patent_cliff.render(scope="major_franchises", horizon="2032")
12 assets trackedDrug / FranchiseRev ($B)202420252026202720282029203020312032
KeytrudaMerck
$25B
EXP
—
—
—
—
EliquisBMS/Pfizer
$12.2B
EXP
—
—
—
—
—
—
OpdivoBMS
$9.8B
EXP
—
—
—
—
—
—
OzempicNovo Nordisk
$14.3B
EXP
JanuviaMerck
$3.1B
EXP
—
—
—
—
—
—
XeljanzPfizer
$2.4B
EXP
—
—
—
—
—
—
StelaraJ&J
$10.9B
EXP
—
—
—
—
—
—
—
HumiraAbbVie
$14.4B
—
—
—
—
—
—
—
—
—
ImbruvicaAbbVie/J&J
$6.7B
EXP
—
—
—
—
—
RevlimidBMS
$10.2B
EXP
—
—
—
—
—
—
EntrestoNovartis
$6.4B
EXP
—
—
—
—
—
—
—
TrulicityEli Lilly
$7.4B
EXP
—
—
—
—
—
Revenue at Risk (2026–2028)$76.8B
Critical Expiries in 20265 assets
Largest Single ExposureKeytruda $25B (2028)
FDA Catalyst Calendar — 2026
12 PDUFA Decisions This Year
Color-coded catalyst density overlay. Click any event for probability breakdown.
Current date:2026-02-27
pharma.fda_calendar.render(year=2026, overlay="catalyst_density")
12 PDUFA events
Jan
Feb1
Mar1
Apr1
May1
Jun2
Jul1
Aug1
Sep1
Oct1
Nov1
Dec1
2026-02-14
Ifinatamab deruxtecan55%PoA
BREAKTHROUGH2026-03-28
T-29d
CagriSema74%PoA
PRIORITY2026-04-22
T-54d
Datopotamab71%PoA
STANDARD2026-05-18
T-80d
Tarlatamab77%PoA
BREAKTHROUGH2026-06-15
T-108d
Zilganersen68%PoA
ORPHAN2026-06-30
T-123d
Zanidatamab67%PoA
BREAKTHROUGH2026-07-09
T-132d
Lerodalcibep65%PoA
STANDARD2026-08-30
T-184d
Imetelstat59%PoA
ORPHAN2026-09-03
T-188d
Mirdametinib63%PoA
ORPHAN2026-10-21
T-236d
Deuruxolitinib58%PoA
STANDARD2026-11-14
T-260d
Orforglipron82%PoA
STANDARD2026-12-05
T-281d
Setmelanotide61%PoA
ORPHANFreemium Access — No Credit Card Required
You've already run your first query.
Make it official.
Your therapeutic area. Your coverage universe. Your PDUFA calendar — rendered in real time. The data was waiting for you.
Technical evaluation?</>Explore the API Docs
54-weight ML engine
AUC 0.88
2,210 historical decisions
Real-time PDUFA alerts